MarketCap
Facebook
X
Telegram
Cardiff Oncology Long-Term Debt | CRDF
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Cardiff Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 K | 813 K | 1.46 M | 2.04 M | 2.57 M | - | - | - | - | 14.2 M | 11.2 M | 13.1 M | 323 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.2 M | 102 K | 5.09 M |
Quarterly Long-Term Debt Cardiff Oncology
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 K | - | 813 K | 284 K | 464 K | 640 K | 813 K | 979 K | 1.14 M | 1.3 M | 1.46 M | 1.61 M | 1.75 M | 1.9 M | 2.04 M | 2.17 M | - | 2.44 M | 2.57 M | 2.69 M | 6 K | 8 K | 9 K | 9 K | 9 K | 9 K | 861 K | 861 K | 861 K | 861 K | - | - | - | - | - | - | - | 12.7 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 323 K | 323 K | 323 K | 323 K | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.2 M | 6 K | 4.37 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agios Pharmaceuticals
AGIO
|
21.8 M | $ 32.84 | 3.38 % | $ 1.9 B |  USA |
 |
Cue Biopharma
CUE
|
2.29 M | $ 19.08 | 1.71 % | $ 1.81 B | USA |
 |
Equillium
EQ
|
356 K | $ 1.41 | -3.09 % | $ 80.8 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
15.1 M | $ 1.61 | 0.63 % | $ 91.6 M | USA |
 |
Abeona Therapeutics
ABEO
|
7.81 M | $ 2.35 | -4.28 % | $ 124 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
40.6 M | $ 18.38 | 0.55 % | $ 3.09 B | USA |
 |
PainReform Ltd.
PRFX
|
30 K | $ 0.74 | -6.69 % | $ 480 K |  Israel |
 |
Cleveland BioLabs, Inc.
CBLI
|
1.5 M | - | -7.31 % | $ 49 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
25.7 K | $ 1.01 | -1.46 % | $ 46.8 M | USA |
 |
ADC Therapeutics SA
ADCT
|
1.03 M | $ 1.6 | 5.3 % | $ 203 M |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
144 M | $ 34.22 | 2.0 % | $ 1.97 B | USA |
 |
Ardelyx
ARDX
|
203 M | $ 3.14 | 4.15 % | $ 757 M | USA |
 |
Akebia Therapeutics
AKBA
|
48.2 M | $ 0.57 | 5.2 % | $ 147 M | USA |
 |
Alector
ALEC
|
9.32 M | $ 2.62 | 3.56 % | $ 270 M | USA |
 |
ALX Oncology Holdings
ALXO
|
4.53 M | $ 1.12 | 0.9 % | $ 60.1 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
2.57 B | $ 21.71 | 1.52 % | $ 6.8 B | USA |
 |
Phathom Pharmaceuticals
PHAT
|
209 M | $ 6.28 | 15.34 % | $ 458 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
806 K | $ 3.88 | 1.44 % | $ 743 M |  Canada |
 |
Agenus
AGEN
|
30.5 M | $ 7.24 | 3.06 % | $ 215 M | USA |
 |
AbCellera Biologics
ABCL
|
137 M | $ 12.15 | -2.53 % | $ 3.63 B | Canada |
 |
Artelo Biosciences
ARTL
|
29 K | $ 2.2 | 2.7 % | $ 416 K | USA |
|
Immatics N.V.
IMTX
|
12.9 M | $ 6.69 | 4.13 % | $ 819 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
3.76 M | $ 0.77 | -28.31 % | $ 243 K | USA |
 |
Aligos Therapeutics
ALGS
|
122 K | $ 2.17 | -15.56 % | $ 21.5 M | USA |
 |
Aclaris Therapeutics
ACRS
|
1.56 M | $ 4.35 | 4.82 % | $ 533 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
127 M | $ 29.93 | 1.94 % | $ 4.54 B | USA |
 |
Cellectar Biosciences
CLRB
|
309 K | $ 1.21 | -0.82 % | $ 3.16 M | USA |
|
Larimar Therapeutics
LRMR
|
2.96 M | $ 2.74 | 1.67 % | $ 228 M | USA |
 |
Replimune Group
REPL
|
83.3 M | $ 21.77 | -6.49 % | $ 2.02 B | USA |
 |
Biofrontera AG
BFRA
|
20.1 M | - | -8.24 % | $ 105 M | Germany |
 |
Pharming Group N.V.
PHAR
|
6.7 M | $ 13.4 | 2.92 % | $ 9.23 B |  Niderland |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
2.48 M | - | -6.97 % | $ 657 M | USA |
 |
Capricor Therapeutics
CAPR
|
14.3 M | $ 11.21 | 26.38 % | $ 521 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
620 M | $ 28.59 | -1.62 % | $ 1.34 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
40 M | - | 1.68 % | $ 4.65 B |  China |
 |
Aquestive Therapeutics
AQST
|
45 M | $ 3.59 | 1.85 % | $ 384 M | USA |
 |
Jaguar Health
JAGX
|
892 K | $ 0.48 | 10.08 % | $ 1.12 M | USA |
 |
Arvinas
ARVN
|
400 K | $ 6.92 | -0.36 % | $ 491 M | USA |
 |
Cerus Corporation
CERS
|
10.2 M | $ 2.12 | 8.46 % | $ 404 M | USA |
 |
Beam Therapeutics
BEAM
|
140 M | $ 25.99 | 3.34 % | $ 2.57 B | USA |
 |
Pulmatrix
PULM
|
8.33 M | $ 1.31 | -2.96 % | $ 4.78 B | USA |
 |
Fortress Biotech
FBIO
|
52.4 M | $ 2.02 | 5.65 % | $ 56.4 M | USA |
 |
Inhibrx
INBX
|
1.11 M | $ 90.76 | 0.17 % | $ 4.28 B | USA |
 |
Entera Bio Ltd.
ENTX
|
260 K | $ 3.21 | -0.9 % | $ 148 M | Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
207 M | - | - | $ 459 M | USA |
 |
Legend Biotech Corporation
LEGN
|
87.2 M | $ 19.66 | -3.7 % | $ 7.25 B | USA |
 |
CytomX Therapeutics
CTMX
|
4.24 M | $ 2.15 | 8.59 % | $ 297 M | USA |
 |
Krystal Biotech
KRYS
|
7.57 M | $ 310.6 | 1.34 % | $ 8.99 B | USA |